BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac

• Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac N.V. (NASDAQ: CVAC).

• CureVac, earlier this month, filed a lawsuit in Germany against BioNTech over its use of mRNA technology.

• Related: CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech.

• It did not rule out further legal action against BioNTech's partner Pfizer.

• BioNTech said that CureVac's U.S. patents, which BioNTech claims not to violate, were equivalent to German patents invoked by CureVac in the German court case, Reuters reported.

• CureVac said that it was aware of BioNTech's legal action but had not yet been formally served.

• "We will review the matter legally in detail and represent our position accordingly," it added.

• Price Action: CVAC shares are down 0.37% at $13.42, and BNTX stock is down 1.52% at $159.91 during the market session on the last check Tuesday.

• Photo by x3 from Pixabay

See more from Benzinga

• WHO, UNICEF Sound Alarm As Pandemic Leads Largest Fall In Kids Vaccinations In 30 Years

• GSK Completes Spin Off Of Its Consumer Healthcare Business

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.